2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162857
    Heme Oxygenase-1-IN-3 1043712-39-5 98%
    Heme Oxygenase-1-IN-3 (compound 4) is a highly selective heme oxygenase-1 (HO-1) inhibitor (Kd=141 nM) that can be used in the research of cancer and neurodegenerative diseases.
    Heme Oxygenase-1-IN-3
  • HY-162860
    FO-4-15 1030759-58-0 98%
    FO-4-15 is an mGluR1/CaMKIIα activator. FO-4-15 has a protective effect against H2O2 in human neuroblastoma (SH-SY5Y) cells. FO-4-15 can improve cognitive impairment in Alzheimer’s disease mice by activating the mGluR1/CaMKIIα pathway, and can reduce Aβ accumulation, hyperphosphorylated Tau, and synaptic damage.
    FO-4-15
  • HY-162908
    TRPV1/CB2 agonist 1 98%
    TRPV1/CB2 agonist 1 (compound 41) is a TRPV1/CB2 agonist, with an EC50 of 26.8 μM for hTRPV1. TRPV1/CB2 agonist 1 can be used in nervous system related research.
    TRPV1/CB2 agonist 1
  • HY-162913
    GSK-3β inhibitor 20 3044109-48-7 98%
    GSK-3β inhibitor 20 (compound 3A) is an potent inhibitor of GSK-3β with an IC50 value of 74.4 nM.
    GSK-3β inhibitor 20
  • HY-162915
    AChE-IN-75 98%
    AChE-IN-75 (N-(2′-methyl)allylnorgalanthamine) is an AChE inhibitor. AChE-IN-75 can be used in Alzheimer's disease research.
    AChE-IN-75
  • HY-162916
    AChE-IN-76 98%
    AChE-IN-76 (compound 6) is an inhibitor of acetylcholinesterase with an IC50 value of 7.6 nM.
    AChE-IN-76
  • HY-162922
    MAP4K4-IN-6 98%
    MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor (IC50: 80 nM). MAP4K4-IN-6 reduces the c-Jun phosphorylation. MAP4K4-IN-6 has neuroprotective effects. MAP4K4-IN-6 increases the viability of motor neurons. MAP4K4-IN-6 can be used for research of Amyotrophic lateral sclerosis (ALS).
    MAP4K4-IN-6
  • HY-162925
    CGRP antagonist 6 98%
    CGRP antagonist 6 (Compound 23) is a CGRP receptor antagonist (Ki: 0.84 nM). CGRP antagonist 6 can be used for research of migraine.
    CGRP antagonist 6
  • HY-162928
    RIPK1-IN-26 2252271-96-6 98%
    RIPK1-IN-26 (Compound 8a) is a potent receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with cell anti-necroptosis potency. RIPK1-IN-26 demonstrats good metabolic stability and good binding specificity in mice. RIPK1-IN-26 is promising for research of PET imaging probe development and neurodegenerative disorders.
    RIPK1-IN-26
  • HY-162977
    Orexin receptor activator-1 3038645-77-8 98%
    Orexin receptor activator-1 is an Orexin Receptor agonist. Orexin receptor activator-1 can be used to study orexin-related diseases.
    Orexin receptor activator-1
  • HY-162978
    DGAT2-IN-3 3037141-61-7 98%
    DGAT2-IN-3 (compound 9) is a DGAT2 inhibitor, with IC50 of 0.4 nM. DGAT2-IN-3 can be used in the research of steatohepatitis, diabetes and cardiovascular diseases.
    DGAT2-IN-3
  • HY-163017
    NP-5497-KA 98%
    NP-5497-KA is a κ-opioid receptor agonist. NP-5497-KA has orally activity[1].
    NP-5497-KA
  • HY-163027
    R079 2115659-62-4 98%
    R079 (compound 17) is a selective, orally active Nrf2 activator. R079 increases Nrf2 translocation activity (EC50 = 32.41 μM). R079 can neutralize excess levels of reactive oxygen species through activating Nrf2. R079 has anti-inflammatory properties and can be used in multiple sclerosis research .
    R079
  • HY-163031
    MAO-B-IN-28 3028096-72-9 98%
    MAO-B-IN-28 (compound 10e) is a potent hMAO-B inhibitor with an IC50 of 1.9±0.5 nM. MAO-B-IN-28 can be used as a candidate for neurodegenerative diseases research.
    MAO-B-IN-28
  • HY-163065
    σ1 Receptor/μ Opioid receptor modulator 2 3009018-61-2 98%
    σ1 Receptor/μ Opioid receptor modulator 2 (compound 4x) is a dual μOR agonist/σ1R antagonist, and displays picomolar μOR agonism activity (EC50: 0.6 ± 0.2 nM) and good σ1R inhibitory activity (Ki: 363.7 ± 5.6 nM). σ1 Receptor/μ Opioid receptor modulator 2 exhibits robust analgesic effects in various pain models.
    σ1 Receptor/μ Opioid receptor modulator 2
  • HY-163116
    Anti-inflammatory agent 67 98%
    Anti-inflammatory agent 67 (compound 7a) is a dual inhibitor of carbonic anhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), and has anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 67 has IC50s of 10.4 μM and 50 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 67 binding to different isoforms of carbonic anhydrase are 48.3 nM (CA I), 42.2 nM (CA II), 52.3 nM (CA IX), and 13.3 nM (CA XII).
    Anti-inflammatory agent 67
  • HY-163117
    Anti-inflammatory agent 68 98%
    Anti-inflammatory agent 68 (compound 7b) is a dual inhibitor of carbonic anhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), with anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 68 has IC50s of 12.6 μM and 60 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 68 binding to different isoforms of carbonic anhydrase are 52.6 nM (CA I), 79.1 nM (CA II), 58.1 nM (CA IX), and 17.2 nM (CA XII).
    Anti-inflammatory agent 68
  • HY-163131
    Glucosylceramide synthase-IN-4 2776965-41-2 98%
    Glucosylceramide synthase-IN-4 (compound 12) is a potent glucosylceramide synthase (GCS) inhibitor, with an IC50 of 6.8 nM. Glucosylceramide synthase-IN-4 shows excellent PK properties and stability in human hepatocytes. Glucosylceramide synthase-IN-4 has good CNS penetration and acceptable PXR selectivity.
    Glucosylceramide synthase-IN-4
  • HY-163150
    5-HT6R antagonist 3 98%
    5-HT6R antagonist 3 (compound 15) is a potent, selective and brain-penetrant 5-HT6R antagonist with Ki values of 14 nM, 3533 nM, 35 nM, 1449 nM for 5-HT6, 5-HT1A, 5-HT2A, 5-HT7, respectively. 5-HT6R antagonist 3 shows anxiolytic-like and properties neuroprotective and procognitive-like effects. 5-HT6R antagonist 3 has the potential for the research of Alzheimer’s Disease.
    5-HT6R antagonist 3
  • HY-163151
    JE-133 2579171-69-8 98%
    JE-133 is an optically active isochromane-2H-chromene conjugate. JE-133 exhibits antioxidant and anti-inflammatory activities. JE-133 is a neuroprotective agent that effectively inhibits neuronal oxidative damage associated with PI3K/Akt and MAPK signaling pathways. JE-133 can also inhibit lipopolysaccharide (LPS) (HY-D1056)-induced neuroinflammation by regulating JAK/STAT and Nrf2 signaling pathways.
    JE-133
Cat. No. Product Name / Synonyms Application Reactivity